Impending US Hemp Ban Threatens CBD Products and Medicare Pilot Program
How US hemp ban could criminalize CBD products – and derail Medicare plan
The Guardian
Image: The Guardian
The recent hemp ban passed by Congress could undermine a new Medicare pilot program that reimburses patients for hemp-derived products, including CBD. Set to take effect on November 12, the ban would criminalize most hemp products, impacting both consumers and businesses reliant on these products for health benefits.
- 01The Centers for Medicare and Medicaid Services has initiated a pilot program allowing reimbursement for up to $500 worth of hemp-derived products annually for eligible patients.
- 02The hemp ban, effective November 12, would criminalize products containing more than 0.4mg of THC, affecting the majority of CBD products currently on the market.
- 03Senator Ron Wyden has reintroduced the Cannabinoid Safety and Regulation Act to replace the ban with regulations ensuring product safety.
- 04Advocates have raised concerns about contamination in hemp products, highlighting the need for quality control regulations.
- 05If the ban is enforced, hemp product manufacturers may have to alter their formulations, potentially reducing the effectiveness of their products.
Advertisement
In-Article Ad
The Centers for Medicare and Medicaid Services (CMS) has launched a pilot program aimed at reimbursing Medicare and Medicaid recipients for up to $500 worth of hemp-derived products, including CBD, each year. This initiative is designed to assess whether these products can help lower overall health costs. However, a hemp ban passed by Congress is set to take effect on November 12, which would criminalize most hemp products by defining hemp as anything containing more than 0.4mg of THC. This change threatens to eliminate the vast majority of CBD products from the market, as stated by Jonathan Miller of the US Hemp Roundtable. Lawmakers like Senator Ron Wyden are pushing for alternative legislation, such as the Cannabinoid Safety and Regulation Act, to ensure safety regulations rather than an outright ban. Concerns about product contamination have also emerged, with advocates arguing that the focus should be on ensuring quality rather than criminalizing certain cannabinoids. If the ban is enforced, manufacturers like Inesa Ponomariovaite may have to drastically alter their products, which could diminish their therapeutic effects.
Advertisement
In-Article Ad
The hemp ban could significantly affect consumers relying on CBD products for health benefits, as well as businesses that produce these products.
Advertisement
In-Article Ad
Reader Poll
Should Congress prioritize regulating hemp products instead of banning them?
Connecting to poll...
More about Centers for Medicare and Medicaid Services
Read the original article
Visit the source for the complete story.